摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1,3,7-三丙基黄嘌呤 | 102284-68-4

中文名称
1,3,7-三丙基黄嘌呤
中文别名
——
英文名称
1,3,7-Tripropylxanthine
英文别名
1,3,7-tripropylpurine-2,6-dione
1,3,7-三丙基黄嘌呤化学式
CAS
102284-68-4
化学式
C14H22N4O2
mdl
——
分子量
278.354
InChiKey
PMJKNRZFAZJNRA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    461.2±37.0 °C(Predicted)
  • 密度:
    1.20±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    20
  • 可旋转键数:
    6
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.64
  • 拓扑面积:
    58.4
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    3,9-二氢-1,3-二丙基-1H-嘌呤-2,6-二酮 在 palladium on activated charcoal 氢气potassium carbonate 作用下, 以 乙醇N,N-二甲基甲酰胺 为溶剂, 35.0 ℃ 、275.79 kPa 条件下, 反应 24.33h, 生成 1,3,7-三丙基黄嘌呤
    参考文献:
    名称:
    Analogs of caffeine and theophylline: effect of structural alterations on affinity at adenosine receptors
    摘要:
    A variety of analogues of caffeine and theophylline in which the 1-,3-, and 7-methyl substituents have been replaced with n-propyl, allyl, propargyl, and isobutyl and, in a few cases, with chloroethyl, hydroxyethyl, or benzyl were assessed for potency and selectivity as antagonists at A1- and A2-adenosine receptors in brain tissue. Caffeine and theophylline are nonselective for these receptors. Nearly all of the 22 analogues of caffeine are more potent than caffeine itself at adenosine receptors. Replacement of the 1-methyl moiety with n-propyl, allyl, or propargyl substituent has little effect on potency at the A1 receptor while enhancing potency about 7- to 10-fold at the A2 receptor. 3,7-Di-methyl-1-propylxanthine is only slightly (1.4-fold) more potent than caffeine at the A1 receptor while being 10-fold more potent at the A2 receptor. 1,3-Di-n-propyl-7-methylxanthine is also selective for the A2 receptor, being 8-fold more potent than caffeine at the A1 receptor and 40-fold more potent at the A2 receptor. A number of other caffeine analogues including 3,7-dimethyl-1-n-propylxanthine, 7-allyl-1,3-dimethylxanthine, and 1,3-dimethyl-7-propargylxanthine are also somewhat selective for the A2 receptor. The most potent caffeine analogue was 1,3-di-n-propyl-7-propargylxanthine, which was about 100-fold more potent than caffeine at both A1 and A2 receptors. The 10 theophylline analogues were relatively nonselective except for the 1-ethyl analogue and the 1,3-diallyl analogue, which were selective for the A2 receptor, and the 1,3-di-n-propyl, 1,3-diisobutyl, and 1,3-dibenzyl analogues, which were somewhat selective for the A1 receptor. 1,3-Di-n-propylxanthine was 20-fold more potent than theophylline at the A1 receptor and 5-fold more potent at the A2 receptor.
    DOI:
    10.1021/jm00157a035
点击查看最新优质反应信息

文献信息

  • SYNERGISTIC ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS USING CURCUMINOIDS OR METHYLXANTHINES
    申请人:Metaproteomics, LLC
    公开号:EP1718312A2
    公开(公告)日:2006-11-08
  • Pharmaceutical compositions comprising hops extract derivatives and caffeine
    申请人:Metaproteomics, LLC
    公开号:EP1718312B1
    公开(公告)日:2015-03-25
  • EP2338481A2
    申请人:——
    公开号:EP2338481A2
    公开(公告)日:2011-06-29
  • Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
    申请人:Babish G. John
    公开号:US20050191375A1
    公开(公告)日:2005-09-01
    The invention provides compositions containing a fraction isolated or derived from hops and a methylxanthine. The invention additionally provides compositions containing a fraction derived from hops and a curcuminoid. The invention also provides methods of using such compositions to reduce inflammation.
  • CONTROLLED RELEASE CAFFEINE DOSAGE FORMS
    申请人:KVK-TECH, INC.
    公开号:US20160128943A1
    公开(公告)日:2016-05-12
    Formulations capable of extended or sustained release of high levels of caffeine or analogs, derivatives and metabolites thereof have been developed The formulations contain at least two components capable of releasing the caffeine or related compound differing rates to maintain a desired plasma level.
查看更多